High expression of CD123, the IL-3 receptor α chain (IL-3α), is observed on both leukemic blasts and leukemic stem cells, thus suggesting it can be considered an attractive therapeutic target in AML.
Researchers from Seoul National University presented results of preclinical evaluation of a new TNF-α/OX40L bispecific antibody, IMB-101, being developed for the treatment of rheumatoid arthritis (RA).
Ibio Inc. has expanded its artificial intelligence (AI)-powered technology offering with the launch of Shieldtx, an antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue.
Sparx Biopharmaceutical Corp. has received FDA approval of its IND application for SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody drug candidate.
Researchers from Biontech SE and Genmab BV presented the discovery and preclinical evaluation of a novel Duobody-EpCAMx4-1BB (BNT314/GEN1059), a novel Fc-inert immunomodulatory bispecific antibody (bsAb) designed to boost antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity.
Data regarding an innovative bispecific antibody – CPL-976 (CPBT-0976) – were recently reported by Celon Pharma SA. Bispecific antibodies targeting more than one antigen on cancer cells improve the specificity and effectiveness of the therapy, and could be utilized for targeting the defense mechanisms of cancer cells, such PD-L1 or EGFR, VEGFR and AXL.
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Adimab LLC to discover and develop innovative antibody drugs in the oncology field.
Novarock Biotherapeutics Ltd., a subsidiary of CSPC Pharmaceutical Group Ltd., has received FDA approval of its IND application for NBL-028, a CLDN6-CD137 bispecific antibody.
Ibio Inc. has announced promising in vivo data for three immuno-oncology candidates, anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3, advancing these programs to clinical candidate selection stage.
Biocity Biopharma announced that the U.S. FDA has accepted its investigational new drug (IND) application for BC-3448, a bispecific antibody that targets the T cell marker CD3 and epidermal growth factor receptor (EGFR), bringing antitumor T cells in proximity to EGFR-expressing cells. To reduce the risk of cytokine release syndrome (CRS), a known risk of CD3-targeting antibodies, the bispecific has a higher affinity for EGFR than CD3.
RSS
